Cabaletta Bio, Inc. (NASDAQ: CABA) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $50.00 price target on the stock.
Cabaletta Bio, Inc. (NASDAQ: CABA) had its price target raised by analysts at Citigroup Inc. from $26.00 to $30.00. They now have a "buy" rating on the stock.
Cabaletta Bio, Inc. (NASDAQ: CABA) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $50.00 price target on the stock.
Cabaletta Bio, Inc. (NASDAQ: CABA) had its price target raised by analysts at Wells Fargo & Company from $34.00 to $35.00. They now have an "overweight" rating on the stock.
Cabaletta Bio, Inc. (NASDAQ: CABA) had its price target raised by analysts at HC Wainwright from $25.00 to $30.00. They now have a "buy" rating on the stock.